Smoke or fire? Acute pancreatitis and the liraglutide trials

Diabetes Care

Volumn 38, Issue 6, 2015, Pages 948-950

  Gale, Edwin A M ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; LIRAGLUTIDE; PLACEBO; SITAGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ACUTE PANCREATITIS; CASE CONTROL STUDY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG EFFICACY; DRUG EXPOSURE; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; GALLSTONE; HUMAN; NOTE; POPULATION RESEARCH; RISK ASSESSMENT; BLOOD PRESSURE; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; DRUG EFFECTS; PANCREATITIS; TREATMENT OUTCOME; WEIGHT REDUCTION;

BLOOD PRESSURE; CASE-CONTROL STUDIES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; PANCREATITIS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84952313893     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc15-0346     Document Type: Note

References (17)

1. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemia agents on vascular complications in patients with adult-onset diabetes. III. Clinical implications of UGDP results. JAMA 1971;218:1400-1410.
2. Rosenstock J, Marx N, Johansen OE, Worle HJ; CAROLINA Steering Committee. Cardiovascular effects of diabetes drugs: making the dark ages brighter with Carolina. Ann Intern Med 2013;158:499.
3. Rosenstock J, Marx N, Kahn SE, et al. Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial. Diab Vasc Dis Res 2013;10:289-301.
4. Butler PC, Elashoff M, Elashoff R, Gale EAM. A critical analysis of the clinical use of incretinbased therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-2125.
5. Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugsdFDA and EMA assessment. N Engl J Med 2014;370:794-797.
6. Doyle AC. A scandal in Bohemia. In: The Adventures of Sherlock Holmes (1892). London, Reprinted in Penguin Popular Classics, 2007, p. 68.
7. Jensen TM, Saha K, Steinberg WM. Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials. Diabetes Care 2015;38:1058-1066.
8. Parks M, Rosebraugh C. Weighing risks and benefits of liraglutidedthe FDA's review of a new antidiabetic therapy. N Engl J Med 2010; 362:774-777.
9. Opie EL. Disease of the Pancreas. Its Cause and Nature. 2nd ed. Philadelphia, London, JB Lippincott and Company, 1910.
10. Modolell I, Guarner L, Malagelada JR. Vagaries of clinical presentation of pancreatic and biliary tract cancer. Ann Oncol 1999;10(Suppl. 4): 82-84.
11. U.S. Food and Drug Administration. Saxenda [prescribing information]. Available from http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/206321Orig1s000lbl.pdf. Accessed 9 April 2015.
12. Perfetti R, Zhou J, Doyle ME, Egan JM. Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. Endocrinology 2000;141:4600-4605.
13. Nyborg NC, Mølck AM, Madsen LW, Knudsen LB. The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species. Diabetes 2012;61:1243-1249.
14. Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC. Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 2013;62:2595-2604.
15. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015;347:78-81.
16. Koehler JA, Baggio LL, Yusta B, et al. GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 2015;21:379-391.
17. Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras (G12D) mouse model. Diabetes 2012;61: 1250-1262.